# Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years

> **NCT03101462** · PHASE4 · COMPLETED · sponsor: **St. Louis University** · enrollment: 38 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Inactivated Influenza Vaccine
- **BIOLOGICAL:** Live Attenuated Influenza Vaccine

## Key facts

- **NCT ID:** NCT03101462
- **Lead sponsor:** St. Louis University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-24
- **Primary completion:** 2011-05-13
- **Final completion:** 2011-11-09
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2019-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03101462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03101462, "Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03101462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*